Stocks · News reference

Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression

Sep 9, 2026, 5:18 PMVandana Singh

Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 10, 2026, 10:41 AMBenzinga Newsdesk
Compass Pathways Announces U.S. Healthcare Provider Grant Program Recipients To Create Training For Delivery Of Psychedelic Treatments
These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected
CMPS
BenzingaSep 9, 2026, 5:32 PMBenzinga Newsdesk
Compass Pathways shares are trading higher after the company announced the topline 52-week results from its Phase 3 COMP005 trial of COMP360 for treatment-resistant depression TRD.
CMPS
BenzingaSep 9, 2026, 10:37 AMBenzinga Newsdesk
Compass Pathways Shares Topline 52-week Results (Part C) From Its Phase 3 COMP005 Trial Of Comp360 For Treatment-Resistant Depression, Showing Additional Benefit Extending Durability Out To 1 Year
Notable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants who were randomized
CMPS